The Commission has adopted a legal proposal which would see pharmaceutical companies pay specific fees for Union-wide pharmacovigilance activities.
This is due to the recent legislation on pharmacovigilance applicable in the EU since July 2012, which significantly broadens the tasks of EMA - a decentralised EU agency, reinforcing its role as a hub for the coordination of the scientific resources made available by the Member States.
The proposal lays down the structure and level of these fees, and will now be discussed by the European Parliament and the Council.
The EU has rules for the strict assessment of the quality, safety and efficacy of medicines before they are placed on the market. This, and the continued safety monitoring of these medicines through pharmacovigilance, aim at ensuring Europeans that the medicines they take are safe, of high quality and that they work.
This news arises from information provided by external entities to the UEMS. The information and views set out in this news are those of the author(s) and do not necessarily reflect the official opinion of the UEMS. Sole responsibility for this content lies with the author(s) and the UEMS cannot be held responsible for any use that may be made of the information contained therein.